Berberine Side Effects and Drug Interactions: What You Need to Know

Berberine is natural. So are caffeine, nicotine, grapefruit compounds, and hundreds of substances capable of changing how the body works.

“Natural” describes where something comes from. It does not tell you whether it can cause diarrhea, constipation, nausea, a medication interaction, a blood-pressure change, a low-glucose episode, an allergic reaction, or a heart-rhythm problem in a susceptible person.

That does not mean berberine is broadly dangerous. In many clinical trials, it has been reasonably well tolerated, and serious adverse events have been uncommon. Digestive complaints are the side effects reported most consistently. However, the safety evidence has limits. Many studies were small, short, conducted in selected populations, inconsistent in how they collected adverse events, or not designed to detect rare problems.

Drug interactions deserve special care. A human crossover study found that repeated berberine administration decreased the activity of three enzymes that help process many medicines. A clinical study in transplant recipients found higher cyclosporine exposure with berberine. Recent case reports have also raised concern about QT prolongation and dangerous ventricular arrhythmias in susceptible or high-exposure situations.

The correct conclusion is not “berberine is unsafe.” It is that a serious safety answer requires the exact product, full medication and supplement list, health history, intended use, and a clear plan for what happens if symptoms appear.

Quick answer: The most consistently reported berberine side effects are abdominal discomfort, bloating or gas, diarrhea, constipation, nausea, and vomiting. Rash and reduced appetite have also been reported. Berberine may interact with medicines through additive effects, changes in drug-metabolizing enzymes or transport, and other mechanisms. Human evidence is particularly important for cyclosporine and for CYP2D6, CYP2C9, and CYP3A4 activity. People who take medication, have a heart-rhythm condition, use transplant or narrow-therapeutic-index drugs, are pregnant or breastfeeding, or are considering use for a child should not rely on a generic interaction list. Have a physician or pharmacist review the exact product before use.

Medical note: This article is educational and is not medical advice. Do not use it to start, stop, replace, space, or adjust prescription treatment. Berberine should not be used during pregnancy or breastfeeding and should not be given to infants. Seek urgent or emergency care for trouble breathing, facial or throat swelling, fainting, seizure, chest pain, a sustained or irregular racing heartbeat, severe confusion, signs of stroke, or persistent vomiting with dehydration.

Editorial disclosure: Metabolic Clarity Labs develops and sells metabolic-health products. That financial interest is why our safety standard should be explicit. Common effects, demonstrated human interactions, possible mechanisms, and isolated case reports should never be blended into one sensational list. Any MCL product should be evaluated against the same standard described here.

The answer depends on what “side effect” means

A side effect is an unwanted effect that occurs when a product is used. An adverse event is something unfavorable that happens during or after use, whether or not the product caused it. A drug interaction occurs when another substance changes a medicine's effect or exposure, or when the combined effects create a problem.

Those categories overlap, but they are not interchangeable.

Someone can develop diarrhea after starting berberine, and the timing may make berberine a reasonable suspect. Someone can also develop dizziness because of dehydration, low glucose, low blood pressure, an unrelated illness, another medication, or several factors together. A report that two things happened together is not always proof of causation.

Four evidence levels matter

Evidence level	What it means	Berberine example	What it does not prove
Commonly reported effect	Appears repeatedly in official guidance and human trials.	Nausea, diarrhea, constipation, bloating, and abdominal discomfort.	It does not predict who will experience it or how severe it will be.
Demonstrated human interaction signal	A controlled or clinical human study found a measurable change.	Reduced CYP2D6, CYP2C9, and CYP3A4 activity; increased cyclosporine exposure.	It does not establish the size or consequence of an interaction with every drug using that pathway.
Possible or theoretical interaction	Mechanism, laboratory, animal, or indirect evidence raises concern.	Additive glucose or blood-pressure effects; possible interactions with some enzyme substrates.	It is not the same as a confirmed clinical interaction in the reader's regimen.
Case report or safety signal	A serious event was described in one or a few people.	Recent reports of QT prolongation and torsades de pointes after berberine exposure.	It cannot estimate incidence or prove that typical use causes the event broadly.

This ladder prevents two common errors.

The first is minimization: “It is only a supplement, so there is nothing to review.”

The second is exaggeration: “One case report proves berberine commonly causes cardiac arrest.”

Neither conclusion is evidence based.

What official health sources say

The National Center for Complementary and Integrative Health identifies abdominal pain, constipation, diarrhea, nausea, and vomiting as the most common adverse effects of oral berberine. It also warns that berberine may interact negatively with medicines and should not be used during pregnancy or breastfeeding or given to infants.

The NCCIH diabetes supplement guide similarly lists nausea, diarrhea, bloating, and constipation and tells people who take medicine to speak with a healthcare provider before taking berberine.

The NIH Office of Dietary Supplements explains a broader principle: supplements contain active ingredients, may cause strong effects, can interact with medicine, and may create additional risk when used at high amounts, with many other supplements, or instead of prescribed treatment.

What “generally well tolerated” means

It means that many participants in the studied settings completed treatment without a serious recognized adverse event. It does not mean:

• everyone tolerates the product;
• every commercial formulation has the same safety profile;
• rare effects have been ruled out;
• every medication combination has been tested;
• long-term use has been fully characterized;
• people excluded from trials face the same risk; or
• a mislabeled or contaminated product is safe.

What clinical trials can miss

Rare adverse effects may not appear in a trial with dozens or even hundreds of participants. Short trials cannot establish years of safety. People with complicated disease, pregnancy, significant organ dysfunction, or interacting medicines may be excluded. Adverse-event collection can be inconsistent, and symptoms such as bloating or constipation may be underreported.

The phrase “no serious adverse events were observed” means none were identified within that study. It does not mean serious adverse events are impossible.

The most common berberine side effects are digestive

Digestive symptoms are the clearest and most consistent part of the safety evidence.

Reported effects include:

• diarrhea or loose stools;
• constipation;
• bloating or abdominal distention;
• gas or flatulence;
• abdominal pain or cramping;
• nausea;
• vomiting;
• upset stomach; and
• reduced appetite.

These symptoms can point in opposite directions. Berberine may be associated with diarrhea in one person and constipation in another. A list that describes only one side of the pattern is incomplete.

What the 2008 diabetes pilot found

In the 2008 study by Yin and colleagues, 20 of 58 participants exposed to berberine across the study groups, or 34.5 percent, experienced transient gastrointestinal adverse effects during 13 weeks. The reported events included flatulence, diarrhea, constipation, and abdominal pain.

Fourteen participants had the protocol amount reduced because of gastrointestinal effects. Most of the reported effects occurred within the first four weeks. The study did not identify severe gastrointestinal events when berberine was used alone, and it did not find significant changes in the monitored liver enzymes or creatinine.

This is useful detail, not a universal prediction. The study was small, used a specific protocol, and included combination treatment in some participants. The 34.5 percent figure should not be presented as the rate for every current product or population.

What a larger two-year trial found

A multicenter randomized placebo-controlled trial studied berberine after colorectal adenoma removal. In the safety population, constipation was reported in six of 446 participants assigned to berberine and one of 478 assigned to placebo. No serious adverse events were reported.

That looks different from the 2008 trial. The product, population, daily amount, duration, outcome, and method of collecting adverse events differed. The contrast is a reminder that one study's percentage is not a universal side-effect rate.

Why digestive symptoms still deserve attention

Mild symptoms can become clinically important if they lead to dehydration, poor food intake, missed medication, electrolyte disturbance, or worsening of another condition. Persistent vomiting or diarrhea matters more in someone taking metformin, a diuretic, insulin, a GLP-1 medicine, or a medicine affected by dehydration or kidney function.

Do not keep changing the serving, opening capsules, combining servings, or cycling on and off to solve symptoms without reviewing the exact product and regimen.

Can berberine cause diarrhea?

Yes. Diarrhea has been repeatedly reported in human studies and official guidance. However, not every episode after starting berberine is necessarily caused by berberine.

Other possible contributors include:

• metformin or another medicine;
• a GLP-1 medicine;
• magnesium or another supplement;
• a sugar alcohol or excipient in the product;
• infection or foodborne illness;
• a sudden dietary change;
• underlying gastrointestinal disease; or
• a multi-ingredient formula.

The response should depend on severity and context. Persistent diarrhea, blood in the stool, fever, severe abdominal pain, faintness, reduced urination, or signs of dehydration require medical guidance. Do not assume that taking the product with food or moving it to another time clears the problem.

Can berberine cause constipation?

Yes. Constipation appears in official guidance, diabetes studies, and the two-year colorectal-adenoma trial.

Constipation may also be influenced by hydration, fiber changes, reduced food intake, iron, calcium, GLP-1 medicines, pain medicine, thyroid disease, limited movement, and other factors. Severe pain, vomiting, marked abdominal swelling, inability to pass stool or gas, or blood in the stool deserves prompt evaluation.

Do not automatically add a laxative or increase another supplement without checking for interactions and the cause.

Can berberine cause nausea, vomiting, gas, or abdominal pain?

Yes. These effects are included in federal health guidance and clinical-study reports.

The fact that a symptom is “common” does not make it harmless in every situation. Repeated vomiting can cause dehydration and interfere with prescription absorption. Abdominal pain can reflect a supplement reaction, but it can also signal gallbladder disease, pancreatitis, bowel obstruction, appendicitis, an ulcer, or another problem requiring medical care.

Severe, localized, persistent, or worsening abdominal pain should not be managed as routine supplement intolerance.

Can berberine cause a rash or allergic reaction?

Rash has been reported, including in the Memorial Sloan Kettering Cancer Center's berberine monograph. The frequency and exact cause are not well established.

A reaction can come from berberine, the botanical source, capsule material, colorant, filler, another active ingredient, or contamination. A multi-ingredient product makes attribution harder.

Stop using the product and contact a healthcare professional for a suspected allergic reaction. Hives, facial or throat swelling, wheezing, trouble breathing, fainting, or a rapidly spreading rash require emergency care.

Can berberine cause low blood sugar?

Berberine is studied partly because it may influence glucose. That creates a plausible additive-risk concern when it is combined with insulin or medicines that stimulate insulin release.

The strongest wording must stay calibrated. Some meta-analyses of diabetes trials did not find a statistically significant increase in reported hypoglycemia. Those trials do not prove that the risk is zero for every person or medication combination. Hypoglycemia may be uncommon, inconsistently defined, underreported, or concentrated in people whose regimens differ from the study populations.

The medication context changes the risk

Metformin alone rarely causes hypoglycemia. Insulin and insulin secretagogues, including sulfonylureas and meglitinides, have a different risk profile. Skipped meals, alcohol, illness, unplanned exercise, weight change, kidney dysfunction, and medication errors can add to the problem.

The NIDDK guide to low blood glucose describes possible symptoms including shakiness, hunger, fatigue, dizziness, confusion, irritability, rapid heartbeat, and trouble seeing or speaking. Severe hypoglycemia can cause seizure or loss of consciousness.

People at risk need a clinician-directed plan defining:

• when and how to monitor;
• what number or symptom requires action;
• how low glucose should be treated;
• when medication guidance is needed;
• when another person should administer rescue treatment; and
• when to call emergency services.

Do not use this article to create that plan or adjust a diabetes medicine.

A symptom is not a diagnosis

Dizziness, sweating, fatigue, hunger, headache, and rapid heartbeat can occur with low glucose, but they can also reflect anxiety, dehydration, low blood pressure, infection, arrhythmia, medication effects, or another cause. When possible and safe, follow the individual's established medical plan rather than guessing from symptoms.

Can berberine lower blood pressure too much?

Berberine and berberine-containing products have been studied for blood-pressure effects, but the evidence is limited, heterogeneous, and inconclusive. A systematic review of hypertension research concluded that randomized-trial evidence was not sufficient to establish effectiveness and safety for treating hypertension.

That uncertainty does not eliminate the possibility of additive effects in an individual taking antihypertensive medicine. It means a universal prediction cannot be made.

Lightheadedness, blurred vision, weakness, fatigue, or fainting can occur with low blood pressure, dehydration, heart-rhythm problems, blood loss, illness, or other causes. Check technique, record the actual reading when safe, and contact the clinician managing the blood-pressure plan. Do not reduce prescribed medication on your own.

Chest pain, trouble breathing, fainting, new one-sided weakness, trouble speaking, or another severe symptom requires urgent evaluation.

Can berberine affect heart rhythm?

This question deserves careful wording because the evidence includes laboratory mechanisms and recent case reports, not a population-level estimate of common risk.

Laboratory studies show that berberine can affect hERG potassium channels involved in cardiac repolarization. Inhibition or reduced trafficking of these channels can prolong the QT interval, which can increase vulnerability to a dangerous ventricular rhythm called torsades de pointes in susceptible circumstances.

A 2006 channel study found that berberine blocked hERG channels in experimental systems. Later cell research examined reduced hERG membrane expression and trafficking. These studies establish biological plausibility. They do not tell us the incidence of clinical arrhythmia among typical supplement users.

What recent case reports add

In 2025 and 2026, reports described QT prolongation, polymorphic ventricular tachycardia, torsades de pointes, cardiac arrest, or implantable-defibrillator shocks in people using berberine. The reports included very different contexts. A 2025 JACC case abstract described cardiac arrest and marked QT prolongation in a woman reportedly using 11 grams daily. A separate 2026 JACC case abstract described recurrent ventricular arrhythmia and defibrillator shocks after berberine use in a patient with congenital long-QT syndrome. A 2026 published case report described a 36-year-old woman with QT prolongation and torsades de pointes whose symptoms and electrocardiogram abnormalities resolved after berberine was discontinued.

Case reports can identify a serious signal. They cannot establish how often it happens, prove that every labeled use creates the same risk, or exclude other contributors.

Who needs particular caution

Do not use a generic supplement article to clear berberine if any of these apply:

• congenital long-QT syndrome;
• a history of torsades de pointes or unexplained ventricular arrhythmia;
• unexplained fainting or recurrent palpitations;
• a pacemaker or implanted defibrillator;
• a medicine known to prolong QT;
• low potassium or magnesium;
• significant bradycardia;
• structural heart disease; or
• several interacting medicines.

A cardiologist or pharmacist should review the exact product and regimen. Fainting, a sustained or irregular racing heartbeat, chest pain, seizure, or an implanted-defibrillator shock requires urgent or emergency evaluation.

Does berberine cause liver damage?

Current evidence does not identify berberine as a common cause of clinically apparent liver injury, but that answer needs boundaries.

The NIH LiverTox berberine record states that berberine has not been linked to serum aminotransferase elevations during therapy or published instances of clinically apparent liver injury and assigns it an “unlikely” likelihood score. LiverTox also notes that prospective human studies reporting detailed laboratory safety are limited.

This supports a narrow conclusion: isolated berberine has not emerged as a recognized common liver-injury cause in the available record.

It does not prove that:

• every retail berberine product is free of liver risk;
• multi-ingredient formulas have the same record;
• contamination, substitution, or adulteration cannot cause harm;
• a person with liver disease faces no added concern;
• drug interactions cannot change liver-related risk; or
• indefinite use has been established as safe.

Product identity matters

When a person develops abnormal liver tests after taking a supplement, the product may contain several ingredients, a botanical extract rather than isolated berberine, undeclared substances, or different amounts than the label states. Causality assessment requires the exact bottle, lot, dates, medication list, symptoms, laboratory pattern, and exclusion of other causes.

Yellowing of the skin or eyes, dark urine, pale stool, severe itching, persistent right-upper abdominal pain, unusual bruising, or confusion requires prompt medical evaluation.

Does berberine damage the kidneys?

Short clinical trials often report no significant worsening in creatinine or other kidney measures among selected participants. That does not establish safety for people with chronic kidney disease, acute kidney injury, dehydration, or interacting medicines.

Kidney function can change the handling and risk of many prescriptions even when berberine itself is not primarily cleared in the same way. Vomiting and diarrhea can cause dehydration. Low blood pressure can reduce kidney perfusion. A transplant medicine interaction can create kidney toxicity indirectly.

A 12- or 13-week trial in selected participants cannot rule out all kidney problems or define use in advanced kidney disease.

Reduced urination, marked swelling, severe weakness, confusion, persistent vomiting, or a rapid change in weight or blood pressure deserves medical evaluation.

Drug interactions are more than a list of medicine names

An interaction checker may label a combination major, moderate, minor, possible, or unknown. Those labels are useful only when the underlying evidence and the patient's context are understood.

Berberine can raise interaction concerns through at least five pathways:

1. Additive physiological effects. Two products may both influence glucose, blood pressure, digestion, or heart rhythm.
2. Drug-metabolizing enzymes. Berberine may change the activity of enzymes that help process medicines.
3. Drug transport. Transport proteins can affect absorption, distribution, and elimination.
4. Gastrointestinal effects. Vomiting, diarrhea, constipation, or altered motility may change medication exposure or adherence.
5. Product complexity. Another ingredient, contaminant, or mislabeled amount may be responsible.

The same medicine may use several pathways. The clinical consequence can also depend on the medicine's therapeutic window, the dose, organ function, genetics, duration, and other drugs.

What human research shows about CYP enzymes

A randomized crossover study in healthy men tested enzyme activity before and after two weeks of berberine 300 mg three times daily. Researchers used probe drugs to evaluate CYP3A4, CYP2D6, CYP2C9, CYP2C19, and CYP1A2.

After repeated berberine administration:

• the urinary marker used for CYP2D6 activity changed markedly;
• the losartan-to-metabolite ratio suggested reduced CYP2C9 activity;
• midazolam exposure increased, supporting CYP3A4 inhibition; and
• statistically significant changes were not found for the tested CYP1A2 and CYP2C19 measures.

What this study proves

It proves that, under that short controlled protocol, repeated berberine changed measured activity of CYP2D6, CYP2C9, and CYP3A4 in humans.

What this study does not prove

It does not prove that every substrate drug will have a clinically important interaction. It does not define the effect of every berberine formulation, amount, duration, genotype, age group, or disease state. It does not tell a reader how to change a prescription.

Why the direction of a drug effect is not always simple

If an enzyme helps clear an active medicine, inhibition can increase exposure and side effects. If the enzyme helps activate a prodrug, inhibition can reduce the desired effect. Some drugs use several enzymes and transporters. A label may already account for other inhibitors or inducers.

That is why “berberine makes medications stronger” and “berberine makes medications weaker” are both too broad.

Why a two-hour gap does not clear every interaction

Separating products can help when an interaction occurs mainly because two substances bind each other or compete during absorption. Enzyme inhibition, transporter effects, additive glucose or blood-pressure effects, and QT vulnerability can last beyond the period when two pills sit together in the stomach.

The human CYP study measured changes after two weeks of repeated use. Moving one product from breakfast to lunch would not automatically erase those changes.

There is no universal spacing interval that makes berberine compatible with every medicine. Follow a pharmacist's drug-specific instruction, not a generic two-hour rule.

The interaction evidence by medication category

Medication category	Why concern may exist	Strength of berberine-specific evidence	Appropriate action
Cyclosporine and transplant immunosuppressants	Drug levels can be sensitive to enzyme and transporter changes; toxicity or treatment failure can be serious.	Human clinical pharmacokinetic evidence exists for cyclosporine; case-level concern exists for tacrolimus.	Do not experiment. Involve the transplant or specialty team before use.
CYP2D6, CYP2C9, or CYP3A4 substrates	Repeated berberine changed these enzyme activities in a human probe study.	Human mechanism evidence, but drug-specific clinical consequences vary.	Ask a pharmacist to review every medicine and its therapeutic window.
Insulin and insulin secretagogues	Additive glucose effects may increase hypoglycemia risk.	Plausible and clinically important; trials do not define every combination.	Use only within a clinician-directed glucose and rescue plan.
Metformin and other diabetes medicines	Glucose and gastrointestinal effects may overlap; kidney function and other drugs matter.	Direct combination evidence is limited and heterogeneous.	Review the exact regimen with the prescriber or pharmacist.
Blood-pressure medicines	Additive effects could contribute to low readings or symptoms.	Berberine-specific clinical interaction evidence is limited.	Monitor only as directed and do not alter prescriptions independently.
QT-prolonging medicines or rhythm-sensitive regimens	Berberine affects hERG in laboratory research; recent serious case reports raise a signal.	Mechanistic evidence plus case reports, without a population incidence estimate.	Obtain cardiology or pharmacist review, especially with long-QT risk.
Statins and other lipid medicines	Some use CYP pathways; laboratory research raises combination concerns for certain statins.	Human clinical interaction evidence is incomplete and drug specific.	Do not generalize across statins. Ask a pharmacist about the exact drug.
Anticoagulants and antiplatelet drugs	CYP2C9 and laboratory platelet findings create possible concern for some agents.	Direct clinical berberine interaction evidence is limited.	Do not assume safety or stop anticoagulation. Seek pharmacist review.
Cancer therapy	Narrow therapeutic windows and CYP or transporter pathways can matter; modeling raises concern for bosutinib.	Drug-specific evidence ranges from modeling to limited data.	Involve the oncology pharmacist or treatment team before use.
Sedatives, antidepressants, pain, and psychiatric medicines	Many use CYP2D6 or CYP3A4, and symptoms such as dizziness may overlap.	Pathway evidence exists, but consequences are drug specific.	Review the exact names, formulations, and other substances with a pharmacist.

This table is not a complete interaction checker. A medicine missing from it is not automatically safe.

Berberine and cyclosporine

Cyclosporine is the clearest drug-specific human interaction example in this article.

A clinical and pharmacokinetic study evaluated renal-transplant recipients taking cyclosporine. In the pharmacokinetic portion, adding berberine increased mean cyclosporine exposure and minimum blood concentration and reduced apparent clearance. The larger clinical comparison also found higher final concentration-to-dose measures in the berberine group.

The study's authors proposed CYP3A4 inhibition in the liver or intestine as a likely mechanism. Other mechanisms may contribute.

The lesson is not that a reader should use berberine to reduce a cyclosporine dose. Transplant drugs require specialty oversight and therapeutic drug monitoring. An uncontrolled change can cause toxicity, kidney injury, rejection risk, or both.

Berberine and tacrolimus

Memorial Sloan Kettering reports a pediatric case in which tacrolimus concentrations and renal toxicity increased after berberine was added. A case report cannot quantify the general risk, but tacrolimus has a narrow therapeutic window and requires careful blood-level monitoring.

People taking tacrolimus or another transplant medicine should not add berberine without the transplant team. Do not rely on dose spacing.

Berberine and metformin

The main concerns include overlapping gastrointestinal symptoms, changing glucose patterns, dehydration, kidney function, and the presence of other glucose-lowering medicines.

Metformin itself commonly causes gastrointestinal effects. If diarrhea or nausea appears after adding berberine, timing alone may not identify which product is responsible. Continuing both while reducing food or fluid intake can make the situation harder to interpret.

Metformin alone rarely causes hypoglycemia, but a person's total regimen may include insulin, a sulfonylurea, or another treatment that changes risk. Do not adjust metformin or use berberine as its replacement.

Read our full guide to berberine and metformin for more.

Berberine with insulin, sulfonylureas, or meglitinides

These medicines require special attention because they can cause hypoglycemia. Laboratory research also raises the possibility that berberine and sulfonylureas may affect each other's metabolism, though the clinical significance is not fully established.

The appropriate plan is not simply “use a smaller berberine serving.” It needs the prescribing clinician to define glucose monitoring, low-glucose treatment, thresholds for contacting the office, medication instructions, and emergency response.

Do not skip food, change insulin, or change an insulin-releasing medicine to accommodate a supplement.

Berberine with GLP-1 medicines

Direct clinical interaction research for each GLP-1 medicine and berberine is limited. The most immediate concern is often overlapping gastrointestinal burden.

GLP-1 receptor agonists and related medicines can cause nausea, vomiting, diarrhea, constipation, reduced appetite, and delayed stomach emptying. Berberine may produce several of the same symptoms. Severe or persistent vomiting can cause dehydration and may affect kidney function and absorption of other oral medicines.

The prescribing team should review hydration, nutrition, gallbladder or pancreatic history, other diabetes medicines, and the exact berberine product. Do not add berberine to intensify weight loss or change the GLP-1 medicine without that review.

Berberine with blood-pressure medicines

Do not treat a general “may lower blood pressure” statement as proof that every combination will cause hypotension. Do not treat limited evidence as proof that no interaction is possible either.

Bring the exact antihypertensive names, doses, schedule, home readings, symptoms, kidney function, fluid status, and other supplements to the prescriber or pharmacist. Amlodipine, beta blockers, ACE inhibitors, angiotensin receptor blockers, diuretics, and other agents differ in mechanism and interaction pathways.

If readings change, do not decide which product to reduce from an internet article.

Berberine with statins

The word “statin” covers drugs with different metabolic pathways. Simvastatin and atorvastatin involve CYP3A4 more than some other statins. Laboratory research has raised concern that combining berberine with certain statins could increase CYP3A4 and hERG-related cardiotoxicity. That research does not establish a clinical event rate in ordinary users.

Some small human studies have used berberine alongside statin therapy without identifying a broad serious safety signal. That does not clear every statin, dose, patient, or product.

Ask the pharmacist about the exact statin and full regimen, especially with muscle symptoms, liver-test abnormalities, multiple CYP3A4 inhibitors, kidney disease, or long-QT risk. Do not stop a statin or substitute berberine for cardiovascular-risk treatment.

Berberine with blood thinners

Direct clinical evidence for a berberine-warfarin interaction is limited. Concern is often based on berberine's demonstrated effect on CYP2C9, laboratory findings involving platelets, and the narrow therapeutic window of warfarin.

That is enough to justify pharmacist review, not enough to claim that berberine definitely causes bleeding with every anticoagulant.

Warfarin, apixaban, rivaroxaban, dabigatran, clopidogrel, aspirin, and other antithrombotic agents use different pathways. Do not group them into one mechanism or stop them because of a supplement article. Unusual bruising, persistent nosebleeds, blood in urine or stool, black stool, vomiting blood, severe headache, sudden weakness, or a significant fall requires medical guidance or urgent care depending on severity.

Berberine with antidepressants, sedatives, or pain medicines

Many medicines in these broad categories use CYP2D6, CYP3A4, or both. Others affect heart rhythm, sedation, serotonin, seizure threshold, blood pressure, or bleeding risk. The interaction cannot be predicted from the category name alone.

Bring the exact generic name, formulation, amount, and schedule to the pharmacist. Include alcohol, cannabis, sleep supplements, antihistamines, cough medicine, and over-the-counter pain relievers because they may change the safety picture.

Do not use a two-hour gap as blanket clearance.

Berberine with cancer treatment

Cancer therapy is not a setting for self-directed supplement experiments. Oral targeted drugs, chemotherapy, endocrine therapy, immunotherapy, supportive medicines, and clinical-trial agents can have narrow therapeutic windows or important CYP and transporter pathways.

Memorial Sloan Kettering notes modeling that predicts increased bosutinib exposure with berberine. A model is not the same as a completed clinical interaction trial, but it is enough to involve the oncology pharmacist.

Do not assume that antioxidant, anti-inflammatory, or laboratory anticancer language makes berberine compatible with treatment.

What about antibiotics and anti-infective medicines?

Berberine has antimicrobial activity in laboratory research and a history of use for gastrointestinal infections in some medical traditions. That does not make it a substitute for an antibiotic, antiviral, antifungal, or antiparasitic medicine.

Some anti-infective medicines use CYP pathways, prolong QT, affect the liver or kidneys, or cause diarrhea. Combining products can complicate both safety and interpretation. Severe diarrhea during or after antibiotic use may require evaluation for a specific infection rather than another antimicrobial supplement.

Ask the prescriber or pharmacist about the exact medicine. Do not use berberine to shorten, replace, or “boost” a prescribed course.

Multi-ingredient products create a different interaction problem

A bottle marketed as “berberine support” may also contain cinnamon, chromium, alpha-lipoic acid, milk thistle, bitter melon, probiotics, magnesium, black pepper extract, or other botanicals and nutrients. Each ingredient can add effects, interactions, allergens, and side effects.

Black pepper extract, for example, is often included to change absorption. A glucose-support blend may contain several ingredients with possible additive effects. Magnesium can cause diarrhea. A capsule colorant or botanical excipient can cause a reaction.

Do not attribute the entire formula's safety record to berberine alone. The pharmacist needs the complete Supplement Facts panel and other-ingredients list.

Product quality is part of the safety question

A correct interaction analysis assumes the bottle contains what the label says. That assumption is not always safe.

A 2018 analysis of 15 commercial berberine products found substantial variation between measured content and label claims. The sample was small and does not describe every current product, but it demonstrates why potency, purity, and identity matter.

Safety can be affected by:

• too much or too little declared ingredient;
• a different botanical or chemical form;
• undeclared active ingredients;
• contamination with heavy metals or microbes;
• residual solvents;
• allergens;
• degradation;
• inaccurate serving instructions; and
• multi-ingredient interactions.

What testing should help answer

Useful finished-product, lot-specific documentation should identify:

• the exact product and lot;
• test date and laboratory;
• analytical method;
• specification and result;
• units and serving or sample basis;
• identity and potency;
• relevant heavy-metal and microbiological findings; and
• whether the test covers raw material or the finished product.

“Third-party tested” without the lot, laboratory, method, specification, and result is not enough to verify the safety claims that matter here.

Read our guide on how to evaluate a berberine product for more.

Who should not take berberine without specialist guidance?

Some circumstances require more than ordinary caution.

Pregnancy and breastfeeding

NCCIH advises people who are pregnant or breastfeeding not to use berberine. This is not a question of choosing a smaller serving.

Infants

Berberine should not be given to infants. It can cause or worsen jaundice and may contribute to kernicterus, a life-threatening bilirubin-related brain injury.

Children and adolescents

Adult protocols should not be scaled down by body weight for a child. Pediatric diagnosis, development, medication use, and product quality require specialist oversight.

Transplant recipients

Cyclosporine and tacrolimus have narrow therapeutic windows, and berberine interaction evidence is clinically important. Involve the transplant team before any use.

People with long-QT syndrome or serious rhythm history

Mechanistic evidence and recent case reports make self-directed use inappropriate in congenital long-QT syndrome, prior torsades de pointes, unexplained ventricular arrhythmia, or similar high-risk settings. Involve cardiology and pharmacy.

People with kidney or liver disease

Trials in selected participants do not establish safety in significant organ disease. Dehydration and drug interactions can add risk. The treating clinician should review current laboratory information and the exact product.

People taking several medicines

Polypharmacy increases the chance of overlapping effects and complex pathways. The interaction review should include prescriptions, over-the-counter products, supplements, alcohol, cannabis, and nicotine when relevant.

People preparing for surgery or a procedure

Supplements can affect glucose, blood pressure, heart rhythm, drug metabolism, gastrointestinal function, and the response to anesthesia. Tell the surgeon, anesthesiologist, and procedural team about berberine and every other supplement well in advance.

Do not invent a universal stop date. The team should give product-specific instructions based on the procedure and medication list.

Is berberine safe for long-term use?

Long-term safety is less certain than short-term tolerability.

Many metabolic studies lasted about eight to 16 weeks. The large colorectal-adenoma trial followed assigned use for up to two years and did not report serious adverse events, but it used a particular product, amount, population, and monitoring structure. Its results do not establish indefinite safety for every purpose or formulation.

Longer exposure creates more opportunities for:

• medication changes;
• new diagnoses;
• kidney or liver changes;
• different product lots or formulas;
• cumulative adherence problems;
• unrecognized interactions; and
• continued use after the original purpose has disappeared.

Set a review date rather than assuming that no symptoms means no risk.

How to evaluate a new symptom after starting berberine

This framework helps organize information. It does not diagnose the cause.

Step 1: Identify the exact product

Record the brand, full name, form, amount per capsule, capsules per serving, other active ingredients, excipients, lot number, expiration date, and where it was purchased.

Step 2: Build a timeline

Write down:

• when the product was started;
• the labeled serving used;
• when the symptom began;
• whether it follows each administration;
• any missed or extra servings;
• food, alcohol, illness, exercise, and hydration changes; and
• medication or supplement changes near the same date.

Step 3: Describe the symptom precisely

“I felt bad” is hard to interpret. Record the location, severity, duration, frequency, associated symptoms, objective readings when appropriate, and what made it better or worse.

Step 4: Check for red flags

Do not continue a home experiment when severe symptoms, allergic signs, syncope, chest pain, neurological symptoms, significant bleeding, persistent vomiting, or another urgent concern is present.

Step 5: Contact the right professional

A pharmacist is often best positioned to review interaction pathways and product ingredients. The prescriber needs to interpret medication changes and clinical symptoms. Poison Control can guide unexpected exposure or possible overdose. Emergency services are appropriate for life-threatening symptoms.

Step 6: Preserve the evidence

Keep the bottle, lot number, receipt, photographs of the label, and any certificate of analysis. Record readings and medical visits. Do not discard the product until the healthcare team says it is safe to do so.

Step 7: Do not restart as a test without guidance

Symptoms disappearing after a product is stopped can support suspicion but does not prove causation. Restarting may provoke a more serious reaction. A rechallenge should not be used as a home experiment.

A symptom-response framework

Situation	Examples	Response
Mild but new or persistent symptom	Bloating, mild nausea, constipation, loose stool, reduced appetite, mild rash without systemic symptoms.	Pause further improvisation and contact the clinician, pharmacist, or product manufacturer as appropriate. Review the exact label and regimen.
Concerning symptom or interaction signal	Repeated vomiting, dehydration, significant glucose or blood-pressure change, worsening rash, unusual bruising, persistent palpitations, reduced urination.	Stop the product and obtain prompt medical guidance. Follow the existing condition-specific plan while awaiting help.
Emergency symptom	Trouble breathing, facial or throat swelling, fainting, seizure, chest pain, sustained or irregular racing heartbeat, severe confusion, stroke signs, major bleeding, or severe dehydration.	Call emergency services. Do not rely on an article, chatbot, or product company for emergency management.
Unexpected ingestion or too much product	Extra capsules, child exposure, uncertain amount, or unexpected symptoms after use.	In the United States, call Poison Control at 1-800-222-1222 or use webPOISONCONTROL. Call emergency services for life-threatening symptoms.

How to prepare for a pharmacist interaction review

Bring the pharmacist more than the word “berberine.”

Product information

• Front-label photograph
• Supplement Facts photograph
• Directions and warnings
• Other-ingredients panel
• Brand, form, and serving math
• Lot number and expiration date
• Certificate of analysis if available

Complete regimen

• Prescription medicines
• Over-the-counter medicines
• Vitamins and minerals
• Botanical supplements
• Sleep, energy, pre-workout, and weight-loss products
• Alcohol, cannabis, nicotine, and recreational substances when relevant
• Medication schedule and recent changes

Health context

• Diagnoses
• Allergies
• Pregnancy or breastfeeding status
• Kidney and liver function concerns
• Heart-rhythm history
• Planned surgery or procedure
• Recent illness, vomiting, diarrhea, or dehydration
• The exact reason berberine is being considered

Questions to ask

1. Does this exact product interact with any part of my regimen?
2. Is the concern demonstrated in humans, drug specific, theoretical, or unknown?
3. Could it change a drug level, drug effect, glucose, blood pressure, bleeding risk, or heart rhythm?
4. Would spacing help this specific interaction, or would it remain?
5. What symptoms or readings require stopping and calling?
6. What requires urgent care?
7. What should be monitored and when?
8. Who should make medication decisions if something changes?
9. Does another ingredient in the formula create a separate concern?
10. When should the plan be reviewed again?

Why online interaction checkers disagree

One checker may label an interaction moderate, another may say insufficient evidence, and a third may not list it. The disagreement can result from different evidence databases, update schedules, thresholds, formulations, or interpretations of laboratory research.

An absent entry can mean:

• no meaningful interaction is known;
• the combination has not been studied;
• the database does not cover the supplement well;
• evidence has not been added yet; or
• the product name does not match the database entry.

Treat a checker as a screening tool, not final clearance. A pharmacist can connect the mechanism to the exact medicine, dose, indication, organ function, and therapeutic window.

Reporting a suspected berberine adverse event

The FDA explains how to report a problem with a dietary supplement. Reports can include serious reactions, use errors, and product-quality problems.

An adverse-event report does not by itself prove causation, and reporting databases cannot reliably estimate incidence. They are still important for identifying signals that a clinical trial may be too small to detect.

Keep:

• the product and packaging;
• brand and full product name;
• lot number and expiration date;
• purchase source and date;
• serving used and timeline;
• photographs of every label panel;
• other medicines and supplements;
• symptoms and medical records; and
• laboratory or electrocardiogram results when available.

The manufacturer should also have a process for serious adverse-event reports. Medical care comes before paperwork.

What if someone takes too much berberine?

Do not wait for a universal toxic amount. Product formulations differ, individual vulnerability differs, and the amount may be uncertain.

The National Capital Poison Center advises people with unexpected symptoms after berberine or possible excessive ingestion to use webPOISONCONTROL or call 1-800-222-1222 in the United States. Expert guidance is free and available around the clock.

Call emergency services for collapse, trouble breathing, seizure, severe confusion, chest pain, a dangerous heart-rhythm symptom, or another life-threatening situation.

Do not induce vomiting unless a qualified poison professional instructs you to do so.

A note from Charles

On November 12, 2025, my health stopped being an abstract conversation. My A1C was 7.2 percent, my triglycerides were 1,761 mg/dL, my blood pressure was dangerously high, and I was hospitalized during a frightening metabolic crisis.

About eight months later, my reported A1C was 5.7 percent, triglycerides were 144 mg/dL, fasting glucose was 97 mg/dL, and blood pressure was around 110/80.

Those changes happened under medical care with prescription medication, diet changes, weight loss, movement, sleep, and broader lifestyle work. I take metformin and do not use insulin. This article should not be read as a claim that I take berberine or that berberine produced my lab changes.

I am not a doctor. What my experience taught me is that the medication list is not paperwork. It is part of the treatment. The supplement list belongs on it too.

The goal is not to be frightened of every product. It is to stop pretending that “natural” means invisible to the body, the prescription, or the pharmacist trying to keep the whole plan safe.

Frequently asked questions

What are the most common side effects of berberine?

The most consistently reported effects are digestive: abdominal discomfort, bloating or gas, diarrhea, constipation, nausea, and vomiting. Reduced appetite and rash have also been reported.

How common are berberine side effects?

There is no universal percentage. One small 2008 diabetes study reported transient gastrointestinal effects in 34.5 percent of exposed participants, while a much larger two-year trial reported constipation in about 1 percent of its berberine safety population. Products, populations, protocols, and reporting methods differed.

Do berberine side effects go away?

Some clinical-study symptoms were transient or resolved after the monitored protocol changed or the product stopped. Do not assume every symptom will resolve. Persistent, severe, or worsening symptoms require guidance.

Can berberine cause diarrhea?

Yes. Diarrhea is repeatedly reported. Other medicines, supplements, infections, excipients, and gastrointestinal disease can also cause it. Persistent diarrhea or signs of dehydration deserve medical review.

Can berberine cause constipation?

Yes. Constipation appears in official guidance and clinical trials. Severe pain, vomiting, abdominal swelling, inability to pass stool or gas, or blood in stool requires prompt evaluation.

Can berberine cause nausea or vomiting?

Yes. Both are recognized adverse effects. Repeated vomiting can cause dehydration and interfere with other medicines. Severe or persistent vomiting requires medical guidance.

Can berberine cause stomach pain or bloating?

Yes. Abdominal discomfort, distention, gas, and pain have been reported. Severe, localized, or worsening pain should not be dismissed as ordinary supplement intolerance.

Can berberine cause a rash?

Rash has been reported, but its frequency is uncertain. Stop the product and contact a professional for a suspected reaction. Hives, swelling, wheezing, or trouble breathing requires emergency care.

Can berberine cause low blood sugar?

It may add to glucose-lowering effects, especially with insulin or insulin-releasing medicines. Trials do not establish the risk for every combination. People at risk need a clinician-directed monitoring and rescue plan.

Can berberine lower blood pressure too much?

An additive effect is possible, but berberine-specific interaction evidence is limited. Record actual readings and symptoms and contact the prescriber. Do not adjust blood-pressure medicine independently.

Can berberine cause heart palpitations or an irregular rhythm?

Laboratory studies show effects on hERG channels, and recent case reports describe QT prolongation and dangerous ventricular rhythms in susceptible or high-exposure circumstances. The incidence among typical users is unknown. Palpitations, fainting, chest pain, seizure, or an irregular sustained heartbeat requires prompt evaluation.

Does berberine prolong the QT interval?

Mechanistic research supports a QT-related concern, and case reports have described prolonged QT with serious arrhythmia. People with congenital long-QT syndrome, prior torsades de pointes, QT-prolonging medicines, or unexplained syncope need specialist review.

Can berberine damage the liver?

NIH LiverTox does not identify berberine as a recognized common cause of clinically apparent liver injury, but detailed prospective safety data are limited. Multi-ingredient or contaminated products can have a different risk.

Can berberine damage the kidneys?

Short trials often found no significant kidney-test worsening in selected participants. That does not establish safety in kidney disease, dehydration, or interacting regimens. Transplant-drug interactions can also create kidney toxicity indirectly.

What medications should not be taken with berberine?

There is no complete universal list. Cyclosporine and tacrolimus deserve particular concern, and human research shows effects on CYP2D6, CYP2C9, and CYP3A4. A pharmacist should review the exact medication and supplement list.

Does berberine interact with cyclosporine?

Yes, human clinical pharmacokinetic research found increased cyclosporine exposure with berberine. Do not combine them without the transplant team and therapeutic drug monitoring.

Does berberine interact with tacrolimus?

A case report described increased tacrolimus concentrations and renal toxicity after berberine was added. Because tacrolimus has a narrow therapeutic window, involve the transplant team before any use.

Does berberine interact with metformin?

The combination may create overlapping gastrointestinal effects and change glucose patterns. Kidney function, dehydration, and other diabetes medicines matter. Do not use spacing as a substitute for prescriber or pharmacist review.

Can berberine be taken with insulin?

Only with clinician oversight. Insulin can cause hypoglycemia, so the plan must define monitoring, low-glucose treatment, medication decisions, and emergency thresholds.

Can berberine be taken with a sulfonylurea?

This requires professional review because sulfonylureas can cause hypoglycemia and laboratory research raises possible metabolic interactions. Do not change the prescription or add berberine independently.

Can berberine be taken with a GLP-1 medicine?

Direct interaction evidence is limited, but gastrointestinal effects may overlap. Persistent vomiting, dehydration, gallbladder or pancreatic history, kidney function, and other diabetes medicines should be reviewed with the prescriber.

Can berberine be taken with blood-pressure medicine?

Do not assume compatibility from a generic interaction list. Additive effects and drug-specific pathways may matter. Bring the exact names, schedule, readings, and symptoms to a pharmacist or prescriber.

Can berberine be taken with statins?

Statins differ. Laboratory research raises concerns for some CYP3A4-dependent statins, while limited human combination studies do not establish a broad serious signal. Ask about the exact statin rather than treating the class as one drug.

Can berberine be taken with blood thinners?

Direct clinical evidence is limited, but CYP2C9 and platelet-related concerns justify review, especially with warfarin or another narrow-therapeutic-index regimen. Do not stop anticoagulation or antiplatelet therapy.

Does berberine interact with antidepressants?

Some antidepressants use CYP2D6 or CYP3A4, affect QT, or have other relevant pathways. The answer depends on the exact medicine. Ask a pharmacist to review the complete regimen.

Does berberine interact with antibiotics?

The answer depends on the antibiotic. Some affect QT, CYP pathways, the liver, kidneys, or gastrointestinal tract. Do not use berberine to replace or enhance prescribed anti-infective treatment.

Can a two-hour gap prevent a berberine interaction?

Not universally. Enzyme, transporter, additive physiological, and heart-rhythm interactions can last beyond stomach absorption. Use only drug-specific spacing instructions from a qualified professional.

Should I take berberine with food to prevent side effects?

Food may change tolerability for some products and people, but there is no universal rule that clears symptoms or interactions. Follow the exact label and professional plan. See our full guide on when to take berberine.

Should I lower the berberine amount if side effects occur?

Do not create your own adjustment plan. A lower amount may still be inappropriate, and a serious symptom should not be managed by titration. Stop improvising and contact the appropriate professional.

Can I restart berberine after a side effect goes away?

Do not restart as a home test. A second exposure can reproduce or worsen a reaction. Ask the clinician or pharmacist whether rechallenge is appropriate.

Is berberine safe during pregnancy or breastfeeding?

NCCIH advises against berberine during pregnancy or breastfeeding. It should not be given to infants because of bilirubin and kernicterus risk.

Is berberine safe for children?

Adult protocols should not be scaled down for a child. Pediatric use requires specialist oversight, and berberine should not be given to infants.

Should berberine be stopped before surgery?

Tell the surgical and anesthesia teams well in advance. Do not invent a universal stop interval. The team should give instructions based on the exact product, medicines, procedure, and health status.

Is berberine safe for long-term use?

Long-term safety is less certain than short-term tolerability. One large trial used a specific protocol for up to two years, but that does not establish indefinite safety across products and populations. Set a review date.

What should I do if I take too much berberine?

In the United States, call Poison Control at 1-800-222-1222 or use webPOISONCONTROL for unexpected exposure or symptoms. Call emergency services for a life-threatening situation. Do not induce vomiting unless instructed.

When should I stop berberine and seek medical care?

Stop and obtain guidance for a suspected significant adverse effect or interaction. Trouble breathing, facial or throat swelling, fainting, seizure, chest pain, severe confusion, stroke signs, sustained irregular heartbeat, major bleeding, or severe dehydration requires urgent or emergency care.

The bottom line

Berberine is not harmless because it is natural, and it is not broadly dangerous because side effects exist.

The most reliable safety finding is that digestive symptoms are common enough to matter. Human research also shows that repeated berberine can change CYP2D6, CYP2C9, and CYP3A4 activity. A clinical study found increased cyclosporine exposure. Mechanistic research and recent case reports raise a serious heart-rhythm signal for susceptible or high-exposure situations, but they do not establish how commonly this occurs in typical users.

The safest process is straightforward:

1. Identify the exact product, form, serving, other ingredients, and lot.
2. Bring every medicine and supplement to the interaction review.
3. Separate demonstrated human evidence from theory and case reports.
4. Do not assume that spacing, food, or a lower amount clears an interaction.
5. Define monitoring, stop criteria, and emergency response before use.
6. Preserve the bottle and report a serious suspected reaction.
7. Do not let a supplement replace diagnosis, medication, or medical care.

You can review our own berberine product’s exact form, serving size, directions, warnings, other ingredients, and available testing at the MCL Berberine product page. Hold it to the same safety and transparency standard described here.

Sources and further reading

1. National Center for Complementary and Integrative Health. In the News: Berberine.
2. National Center for Complementary and Integrative Health. Diabetes and Dietary Supplements: What You Need To Know.
3. NIH Office of Dietary Supplements. Dietary Supplements: What You Need to Know.
4. National Center for Complementary and Integrative Health. Using Dietary Supplements Wisely.
5. Yin J, Xing H, Ye J. Efficacy of Berberine in Patients With Type 2 Diabetes Mellitus. Metabolism. 2008;57(5):712-717.
6. Chen YX, et al. Berberine Versus Placebo for the Prevention of Recurrence of Colorectal Adenoma. Lancet Gastroenterology and Hepatology. 2020;5(3):267-275.
7. Dong H, Wang N, Zhao L, Lu F. Berberine in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Evidence-Based Complementary and Alternative Medicine. 2012;2012:591654.
8. Guo J, et al. The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients. Oxidative Medicine and Cellular Longevity. 2021;2021:2074610.
9. Guo Y, et al. Repeated Administration of Berberine Inhibits Cytochromes P450 in Humans. European Journal of Clinical Pharmacology. 2012;68(2):213-217.
10. Wu X, et al. Effects of Berberine on the Blood Concentration of Cyclosporin A in Renal Transplanted Recipients. European Journal of Clinical Pharmacology. 2005;61(8):567-572.
11. Memorial Sloan Kettering Cancer Center. Berberine.
12. National Institute of Diabetes and Digestive and Kidney Diseases. Berberine, LiverTox.
13. Rodriguez-Menchaca AA, et al. Block of hERG Channels by Berberine. Journal of Cardiovascular Pharmacology. 2006;47(1):21-29.
14. Wang Y, et al. Berberine Induces hERG Channel Deficiency Through Trafficking Inhibition. Cellular Physiology and Biochemistry. 2014;34(3):691-702.
15. Itani A, et al. Berberine-Induced Polymorphic Ventricular Tachycardia. JACC. 2025;85(12 Suppl):4214.
16. Bartlett A, et al. Herbal Remedy, Shocking Outcome: QTc-Prolonging Supplement in a Patient With Congenital Long QT Syndrome. JACC. 2026;87(13 Suppl):A1339-A1340.
17. Williams JM, Yadlapalli N, Franchi F. Natural Is Not Always Safe: A Case of Torsades de Pointes Induced by Berberine Supplementation. Cureus. 2026;18(6):e111276.
18. Atefi M, et al. The Effect of Barberry Supplementation on Blood Pressure: A Systematic Review and Meta-Analysis. Complementary Therapies in Medicine. 2021;56:102608.
19. Lan J, et al. Berberine for the Treatment of Hypertension: A Systematic Review. Complementary Therapies in Clinical Practice. 2021;42:101287.
20. Funk RS, et al. Variability in Potency Among Commercial Preparations of Berberine. Journal of Dietary Supplements. 2018;15(3):343-351.
21. National Institute of Diabetes and Digestive and Kidney Diseases. Low Blood Glucose, or Hypoglycemia.
22. U.S. Food and Drug Administration. How to Report a Problem With Dietary Supplements.
23. National Capital Poison Center. Berberine: Benefits and Risks.
24. U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements.